Resources

Vitamins and minerals are essential for healthy growth and development, especially for children and women. This fact sheet describes PATH and partners development of a multiplexed diagnostic panel to support surveillance of micronutrient deficiencies and further support vaccination efforts.

This brief summarizes the findings from a gap analysis conducted by the Advancing Maternal Immunization (AMI) collaboration of experts, which describes the evidence and policy needs of global and country decision-makers, public health program planners, and implementers that may be involved in maternal respiratory syncytial virus (RSV) vaccine decisions or delivery. This brief focuses specifically on the context of potential introduction in low- and middle-income countries and summarizes relevant evidence across the following broad topic areas: 1) disease, 2) product, 3) health economics and financing, and 4) vaccine service delivery.AMI is a collaboration of cross-sectoral experts convened by PATH and the World Health Organization with the purpose of advancing RSV maternal immunization.Related: Advancing Maternal Immunization: A Gap Analysis Report

PATH and our partners are advancing the availability of highly sensitive diagnostic tests for malaria to support elimination strategies.

The Prospective Country Evaluation (PCE) is an independent evaluation of the Global Fund commissioned by the Global Fund's Technical Evaluation Reference Group (TERG). The PCE is designed to evaluate how Global Fund policies and processes play out in country in real time and provide high quality, actionable, timely information to national program implementers and Global Fund policymakers. This brief presents findings from the PCE in Uganda assessing the role and function of partnerships in the 2017 Global Fund application process. It was prepared by the Infectious Diseases Research Collaboration (IDRC), Uganda and PATH, USA, in collaboration with the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, USA.

PATH and our partners are advancing new diagnostic tests for G6PD deficiency that may help guide appropriate clinical care of patients and support P. vivax elimination efforts.